Despite the advancements in health system management and technology, HumanrnImmunodeficiency Virus (HIV), Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) remain arnserious global public health challenge. GB virus (GBV-C) is a virus in the Flaviviridae familyrnwith HCV that was isolated from patients with liver disease. It has the same mode of transmissionrnwith HIV, HBV and HCV. Several studies from different countries have reported the positive rolernof GBV-C in improving the clinical infection and treatment outcomes of HIV patients, while itsrnimpact among HBV and HCV patients is controversy. Although the virus has been isolated fromrnpatients with fulminant hepatitis, but other studies failed to prove any association. Co-infection ofrnGBV-C with one or more hepatotropic viruses like HBV or HCV may have negative or positiverneffect on the disease evolution. In Ethiopia, there has not been any study made on the prevalencernor the clinical impact of GBV-C in circulation. Therefore, the aim of this study was to determinernthe prevalence, predominant genotype and the association between GBV-C and the clinicalrnoutcome among viral hepatitis and HIV patients under HAART.rnSerum samples were collected from different population living in Addis Ababa from March 2014rnto February 2016. The subjects of this study comprised a total of 252 participants of all ages, andrnwere divided into distinct groups according to their health status. The first group comprised arntotal of 81 HIV samples that were sent to the health research laboratory in Addis Ababa forrnfollow-up studies, the second group comprised a total of 101 serum frozen samples collectedrnfrom Adera Internal Medical Specialty Center for patients with viral hepatitis, and 70 frozenrnserum samples of healthy individuals collected from the Ethiopian Public Health and ResearchrnInstitutes and adult volunteers. To determine the prevalence of GBV-C, RNA was extracted,rnreversed transcribed, and amplified by Real Time polymerase chain reaction (PCR), usingrnprimers for 5- untranslated region (5-UTR) of the HGV/GBV-C. Among the HIV patients thernCD4+ cells count and plasma viral load were performed. Liver function test and abdominal ultrarnsound were investigated in all viral hepatitis patients. The prevalence of GBV-C RNA wererndetected in 20 (11.27%) of the patients with viral hepatitis and HIV, while all the healthy subjectsrnwere negatives.rnAmong HIV patientâ€™s comparison of the mean CD4+ count was found to be significantlyrndifferent between HGV/GBV-C positive and negative patients at (P < 0.05). GBV-C and HIVrncoinfected patients were categorized in the first and second WHO clinical staging system.rnFurthermore, positive and negative GBV-C patients were sub divided into small groups based onrnage, sex and date of starting HAART. The number of CD4+ cells over time increased morernrapidly in GBV-C positive patients compared to GBV-C negative patients. Among viral hepatitisrnpatients the prevalence of GBV-C were slightly higher among HBV patients, however, there wasrnno significant difference (P > 0.05) in the liver enzymes level among GBV-C negative andrnpositive individuals. Our study found that GBV-C infection had no influence on the severity ofrnchronic liver disease among HBV and HCV coinfection. While among HIV patients thernvirncoinfection reduces the viral load, increases the number of CD4+ cells and improves response torntreatment.rnTo determine the predominant genotype, serum samples were recollected on 2017, from the samernpatients who were GBV-C positive in 2014. After performing various molecular techniques onrnthe samples, the virus was detected but at a low level in the patientâ€™s serum, which indicates thernclearance of the virus. Therefore it was not possible to sequence the virus.rnTo the best of our knowledge, this is the first report of GBV-C in Ethiopia. Understanding thernmechanisms between GBV-C and HIV could lead to develop novel treatment/vaccine.